Programmed death-ligand 1 (PD- L1) antibody is a type of reagent that is used in medical research

and clinical practice to detect and block the PD-L1 protein. PD-L1 is a protein that is found

on the surface of some cells in the body, including cancer cells, and is known to help them evade

the immune system's response.

PD-L1 antibodies work by binding to the PD-L1 protein and preventing it from interacting with its

receptor on immune cells, which can then stimulate the immune system to attack cancer cells. This

approach is known as immune checkpoint blockade therapy and has shown promise in treating certain

types of cancer, such as melanoma, lung cancer, and bladder cancer.

PD-L1 antibodies are also used in diagnostic tests to determine the level of PD-L1 expression in

tumor cells. This information can help doctors determine which patients are more likely to respond

to immune checkpoint blockade therapy.